Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

regorafenib

Known as: 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide, Regorafenibum 
An orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
BACKGROUND There are no systemic treatments for patients with hepatocellular carcinoma (HCC) whose disease progresses during… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
PURPOSE We evaluated the activity of regorafenib, an oral multikinase inhibitor, in advanced gastric adenocarcinoma. PATIENTS… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND In the international randomised phase 3 CORRECT trial (NCT01103323), regorafenib significantly improved overall… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
PURPOSE We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The combination of target-specific drugs like bevacizumab with chemotherapeutics has improved treatment efficacy in advanced… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Purpose: Regorafenib is a novel oral multikinase inhibitor of angiogenic (VEGFR1-3, TIE2), stromal (PDGFR-β, FGFR), and oncogenic… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Background:In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour… Expand
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 3
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Angiogenesis, a critical driver of tumor development, is controlled by interconnected signaling pathways. Vascular endothelial… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?